GlassScriptPhysician profile
Rahul Sharma
NPI 1447505953
$2,960.03
in general payments reported to CMS, 2019-2025
21 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $191 · 2021: $975 · 2022: $985 · 2023: $286 · 2024: $273 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $650 · Food and Beverage: $138 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $650.00 |
| Food and Beverage | $138.37 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sekisui Diagnostics LLC | $650.00 | 2023-2025 | |
| Abbott Laboratories | $508.29 | 2020-2022 | |
| Novo Nordisk INC | $400.23 | 2021-2022 | |
| Corcept Therapeutics | $366.10 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $209.39 | 2020-2023 | Farxiga |
| Xeris Pharmaceuticals, INC. | $127.67 | 2021-2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.56 | 2020-2022 | |
| Amgen INC. | $117.40 | 2021-2022 | |
| Mannkind Corporation | $102.79 | 2022-2023 | Afrezza |
| Insulet Corporation | $99.85 | 2021-2024 | Omnipod |
| Tandem Diabetes Care, INC. | $64.38 | 2022 | |
| Grt US Holding, INC. | $27.24 | 2022 | |
| Lilly USA, LLC | $24.88 | 2022-2023 | Mounjaro |
| Dexcom, INC. | $21.17 | 2022 | |
| Antares Pharma, INC. | $20.47 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $19.63 | 2021 | |
| Rayner Intraocular Lenses Limited | $18.97 | 2022 | |
| Horizon Therapeutics Plc | $18.87 | 2023 | Tepezza |
| Smith+Nephew, INC. | $14.82 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.51 | 2022 | |
| Zealand Pharma US, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.